Lung function from school age to adulthood in primary ciliary dyskinesia.

"Conflict of interest: P. Latzin reports grants from Vertex and Vifor, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Vertex, Vifor and OM Pharma, and participation on a data safety monitoring board or advisory board for Polyphor, Santhera (DMC), Vertex, OM Pharma and Vifor. M.R. Loebinger reports consultancy fees from Insmed, AstraZeneca and Grifols, and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Insmed and Grifols. The remaining authors disclose no potential conflicts of interest."

"Support statement: This study is supported by Swiss National Science Foundation (320030B_192804). The development of the iPCD Cohort has been funded from the European Union's Seventh Framework Programme under EG-GA number 35404 BESTCILIA: Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia. PCD research at ISPM Bern also receives national funding from the Lung Leagues of Bern, St Gallen, Vaud, Ticino, and Valais, and the Milena-Carvajal Pro Kartagener Foundation. M. Goutaki is supported by a Swiss National Science Foundation fellowship (PZ00P3_185923). Most participating researchers and data contributors participate in the BEAT-PCD clinical research collaboration, supported by the European Respiratory Society and the ERN-LUNG (PCD core). The contribution by the Prague centre was supported by Czech health research council AZV ČR (NV 19-07-00210). Funding information for this article has been deposited with the Crossref Funder Registry."